Does Aetna (CVS Health) Cover Liraglutide?

Aetna's Coverage Policy for Liraglutide

Aetna (CVS Health) classifies liraglutide as a covered medication on its commercial PPO and HMO formularies when prescribed for FDA-approved indications. Those indications include chronic weight management in adults with a BMI of 30 kg/m² or greater (or BMI ≥27 kg/m² with at least one weight-related comorbidity) and as an adjunct to diet and exercise for type 2 diabetes.

The FDA approved liraglutide 3.0 mg (Saxenda) for chronic weight management in December 2014, based on the SCALE Obesity and Prediabetes trial that enrolled 3,731 adults. That trial demonstrated 8.0% mean body weight loss at 56 weeks compared to 2.6% with placebo. Participants receiving liraglutide 3.0 mg were significantly more likely to lose ≥5% of body weight (63.2% vs. 27.1%, P<0.001) [1].

Aetna's clinical policy bulletin requires prescribers to document the specific indication, BMI at treatment initiation, and relevant comorbidities before granting authorization. Plans administered through CVS Caremark as the pharmacy benefit manager follow formulary placement decisions that may shift between Tier 3 and Tier 4 based on annual contract negotiations with Novo Nordisk.

Coverage differs between the weight-management and diabetes indications. For type 2 diabetes (using Victoza, liraglutide 1.8 mg), Aetna typically places the drug at a lower tier with less restrictive prior authorization. The weight-management formulation faces tighter scrutiny because Aetna categorizes anti-obesity medications under a separate utilization management protocol.

Prior Authorization Criteria

Getting liraglutide approved through Aetna requires meeting all elements of the insurer's prior authorization checklist. The process is moderately difficult, but straightforward if your provider submits complete documentation on the first attempt.

Aetna's standard PA criteria for liraglutide (weight management) include documented BMI ≥30 kg/m² or ≥27 kg/m² with at least one comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. The prescriber must also confirm that the patient has participated in a structured lifestyle modification program (diet and exercise counseling) for at least 3 to 6 months prior to the request [2]. The Endocrine Society's 2015 guidelines support pharmacotherapy as an adjunct when lifestyle modifications alone produce insufficient weight loss, which aligns with Aetna's documented rationale for requiring this prerequisite.

Additional documentation requirements:

• Baseline body weight and BMI recorded within 30 days of the request
• List of comorbid conditions with supporting lab work or diagnostic codes
• Documentation of failed or insufficient response to step therapy agents
• Statement confirming no contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome)
• Target treatment duration (typically approved in 6-month increments)

Aetna processes most PA requests within 5 to 7 business days for standard requests. Urgent requests receive a decision within 72 hours. Electronic submissions through the CVS Caremark portal tend to process faster than fax submissions.

Step Therapy Requirements

Aetna mandates step therapy before approving liraglutide for weight management. This means your provider must document that you tried and failed (or are intolerant to) at least one first-line weight-management agent.

Agents that satisfy Aetna's step therapy include orlistat (Alli/Xenical), phentermine, or phentermine-topiramate (Qsymia). Some Aetna plans also accept documented failure of naltrexone-bupropion (Contrave) as fulfilling the step requirement. The minimum trial period Aetna requires is typically 90 days at therapeutic dose unless the patient experienced documented adverse effects requiring discontinuation.

For the diabetes indication (liraglutide 1.8 mg), the step therapy protocol differs. Aetna generally requires trial of metformin as first-line therapy, consistent with the American Diabetes Association Standards of Care position that metformin or lifestyle change should precede injectable GLP-1 receptor agonist therapy unless contraindicated [3].

A documented intolerance counts as meeting the step requirement. If a patient develops GI side effects on orlistat severe enough to discontinue, the prescriber should note the specific adverse event, date of occurrence, and reason for stopping. Vague statements like "patient did not tolerate" without supporting details frequently trigger PA denials.

Formulary Tier and Cost Sharing

Liraglutide's placement on the Aetna/CVS Caremark formulary determines your out-of-pocket cost. Most Aetna commercial plans place liraglutide at Tier 3 (preferred brand) or Tier 4 (non-preferred brand), depending on the specific plan design and year.

At Tier 3, expect copays ranging from $75 to $150 per month or coinsurance of 25% to 35% after deductible. Tier 4 placement typically means coinsurance of 30% to 50% after deductible, which on a $1,349 list price translates to $405 to $675 per fill before reaching any out-of-pocket maximum.

The FDA-approved prescribing information for Saxenda notes that treatment should be discontinued if a patient has not lost at least 4% of baseline body weight by 16 weeks, as continued treatment is unlikely to produce clinically meaningful weight loss [4]. Aetna incorporates this into reauthorization criteria. At the 6-month reauthorization point, the insurer requires documentation of ≥4% weight loss to continue coverage.

Some Aetna plans exclude anti-obesity medications entirely from their pharmacy benefit. Check your specific plan's Summary of Benefits and Coverage document or call the number on the back of your insurance card to verify coverage before your provider submits a PA.

How to Appeal an Aetna Denial

If Aetna denies coverage for liraglutide, you have structured appeal options. The denial letter specifies the exact reason, which is your starting point for building the appeal.

First-level internal appeal. You or your provider must submit a written appeal within 180 days of the denial notice. Include a letter of medical necessity from the prescribing physician that directly addresses each denial reason. If the denial cited insufficient step therapy documentation, attach pharmacy claims history or chart notes proving prior medication trials.

The SCALE Obesity trial data showing statistically significant weight reduction and improvement in cardiometabolic markers can support medical necessity arguments, particularly for patients with multiple obesity-related comorbidities [1]. Dr. Xavier Pi-Sunyer, the trial's lead investigator, noted in the NEJM publication: "Liraglutide 3.0 mg, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control" [1].

External review. If the internal appeal fails, you can request an independent external review through your state's insurance department. External reviewers are physicians not affiliated with Aetna who evaluate whether the denial was clinically appropriate. This process takes 45 to 60 days for standard cases.

Common denial reasons and how to counter them:

• "Insufficient documentation of lifestyle modification": Submit dietitian visit notes, gym records, or structured program enrollment confirmation
• "Step therapy not completed": Provide pharmacy fill history with dates and a statement explaining why the prior agent was inadequate or not tolerated
• "BMI does not meet threshold": Ensure the recorded BMI reflects measurement at the time of request, not an older value from the chart

According to Aetna's clinical policy bulletins, approximately 40% to 50% of first-level appeals for GLP-1 receptor agonists result in overturned denials when complete supporting documentation accompanies the appeal [5].

Manufacturer Savings Cards and Aetna

Novo Nordisk offers a savings card program for Saxenda that can reduce out-of-pocket costs. Whether you can use it with Aetna coverage depends on your specific plan type.

Patients with commercial insurance (including Aetna PPO and HMO plans) are generally eligible for the Novo Nordisk savings card, which can reduce copays to as low as $25 per month for up to 12 months. The savings card cannot be combined with government-funded insurance including Medicare Part D, Medicaid, or Tricare.

There is a cap. The manufacturer savings card covers up to a specified annual maximum (typically $200 to $300 per fill). If your coinsurance after Aetna pays its portion still exceeds that cap, you pay the difference. Patients on Tier 4 plans with 50% coinsurance may find the savings card insufficient to bring costs below $300 per month.

One practical consideration: savings card payments do not count toward your Aetna deductible or out-of-pocket maximum. This means using the card delays the point at which you hit your plan's catastrophic coverage threshold. For patients expecting to reach their out-of-pocket max through other medical expenses, it may be strategically better to pay full coinsurance early in the year.

Diabetes vs. Weight Management Coverage Differences

Aetna applies different utilization management criteria depending on whether liraglutide is prescribed for type 2 diabetes (Victoza, 1.8 mg) or chronic weight management (Saxenda, 3.0 mg). This distinction affects approval likelihood, tier placement, and reauthorization frequency.

For type 2 diabetes, liraglutide typically receives Tier 2 or Tier 3 placement with a simpler PA process. The prescriber needs to document a diagnosis of type 2 diabetes, current HbA1c, and trial of metformin (unless contraindicated). The American Association of Clinical Endocrinology 2023 consensus statement recommends GLP-1 receptor agonists as second-line therapy after metformin for patients with established cardiovascular disease or high cardiovascular risk, which provides strong clinical backing for PA submissions [6].

For chronic weight management, the bar is higher. Aetna requires the additional lifestyle modification documentation, stricter BMI thresholds, and the weight-loss milestone at reauthorization. Some employer-sponsored Aetna plans exclude weight-management medications from the pharmacy benefit altogether while still covering liraglutide for diabetes.

A prescribing strategy some clinicians use: if a patient has both type 2 diabetes and obesity, documenting liraglutide under the diabetes indication (ICD-10 E11.x) rather than the obesity indication (E66.x) may result in faster approval and lower cost sharing. The LEADER cardiovascular outcomes trial demonstrated that liraglutide reduced major adverse cardiovascular events by 13% in patients with type 2 diabetes and established cardiovascular disease (HR 0.87 to 95% CI 0.78-0.97), providing cardiovascular risk reduction beyond glycemic control [7].

Timeline From Prescription to First Fill

The complete process from initial prescription to picking up liraglutide at the pharmacy takes 7 to 21 business days when step therapy is already documented. Here is the typical sequence.

Day 1 to 2: Provider submits PA through CVS Caremark's electronic portal with supporting documentation. Day 3 to 7: Aetna's utilization management team reviews and issues a determination. Day 7 to 10: If approved, the claim processes at the pharmacy. If specialty pharmacy dispensing is required (some plans route Saxenda through CVS Specialty), add 3 to 5 days for shipping.

If the initial PA is denied, the timeline extends by 30 to 45 days for the appeal process. Providers can submit a peer-to-peer review request, which connects your prescriber directly with Aetna's medical director to discuss the case. Peer-to-peer reviews often resolve denials within 3 to 5 business days and are faster than the formal appeal route.

The Endocrine Society notes that delays in initiating pharmacotherapy for obesity can result in continued weight gain and progression of comorbidities, which supports urgent PA requests in clinically appropriate cases [2].

Tips to Maximize Approval Likelihood

Certain documentation practices significantly improve first-pass PA approval rates for liraglutide through Aetna.

Submit complete records on the first attempt. Incomplete submissions are the most common reason for PA delays and denials. Your provider should include all required elements in a single submission rather than sending partial documentation with a plan to supplement later.

Use Aetna's specific form. CVS Caremark publishes condition-specific PA forms that list exactly which fields the reviewer evaluates. Using the correct form rather than a generic letter of medical necessity reduces processing time and rejection for administrative reasons.

Document everything in the EMR. Aetna reviewers look for objective measurements (scale weight, BMI calculation, lab values) rather than subjective assessments. A chart note stating "patient is obese" without a recorded BMI will not satisfy PA criteria.

The Obesity Medicine Association's 2024 position statement emphasizes that "administrative barriers to evidence-based anti-obesity pharmacotherapy contribute to health disparities and delay treatment for a chronic, relapsing disease" [8]. If your initial request is denied, citing professional society positions in your appeal letter demonstrates that the prescribed treatment aligns with current medical consensus.

Patients prescribed liraglutide 3.0 mg for weight management should expect Aetna to reauthorize every 6 months, with the 4% weight-loss threshold applying at each review point.